Comparison of acute and delayed antiemetic effect of adding Aprepitant to Odansitron ‎and Dexamethasone regimen ‎in patients with Hodgkin lymphoma receiving highly emetogenic chemotherapy

Cancer is a class of ‎disease in which group of cells show out of control growth, invasions ‎and ‎sometimes metastasis to different parts of the body. Few side effects of cancer treatment are ‎more feared by the patient than nausea and vomiting. Although nausea and emesis (vomiting ‎and retching) can result from surgery or radiation therapy, chemotherapy-induced nausea ‎and vomiting (CINV) are potentially the most severe and most distressing. A randomized, single-blind controlled clinical trial conducted in Hiwa ‎Center for Cancer in Sulaimani city for the period ‎from January to December 2015. A total of 70 Hodgkin lymphoma patients presented to ‎Hiwa ‎Center for Cancer and treated with ABVD chemotherapy regimen ‎were selected. The patient's ‎received either the treatment (Aprepitant, ‎Odansitron and Dexamethasone) or the standard ‎regimen (Odansitron, ‎Dexamethasone) in a 1:1 ratio, ‎computer-generated, random allocation ‎schedule. A total of sixty-three Hodgkin lymphoma patients were included in ‎the present study ‎with a mean age was 47.8±14.4 years; 34.9 % of them were ‎ageing 60 years and more. Nausea and vomiting score was significantly higher in the treatment group from 2nd day to 4th days; the number of rescue therapy was significantly higher in the standard therapy group. In conclusion, the use of Aprepitant, Odansitron and Dexamethasone regimen ‎showed superior and valuable results in the prevention of cancer ‎induced nausea and vomiting by patients on chemotherapy.